Tumor Necrosis Factor Ligand Superfamily Member 5

Tumor Necrosis Factor Ligand Superfamily Member 5 Uses, Dosage, Side Effects, Food Interaction and all others data.

Tumor Necrosis Factor Ligand Superfamily Member 5 is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).

Trade Name Tumor Necrosis Factor Ligand Superfamily Member 5
Generic Dapirolizumab pegol
Dapirolizumab pegol Other Names Dapirolizumab pegol, Immunoglobulin fab' g1-kappa pegylated, anti-(homo sapiens cd40lg (cd40 ligand, cd40l, tumor necrosis factor ligand superfamily member 5, tnfsf5, tumor necrosis factor related activation protein, trap, cd154)), pegylated humanized monoclonal antibody
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Tumor Necrosis Factor Ligand Superfamily Member 5
Tumor Necrosis Factor Ligand Superfamily Member 5

Innovators Monograph

You find simplified version here Tumor Necrosis Factor Ligand Superfamily Member 5


*** Taking medicines without doctor's advice can cause long-term problems.
Share